- AU$135.09m
- AU$96.64m
- AU$5.91m
Australia's Dimerix hits highest in 2-1/2 years on placement
Brief: Dimerix Announces Placement To Raise A$20 Million At Issue Price Of A$0.30 Per Share
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix Ltd Posts HY Loss Attributable Of A$6.7 Million
Dimerix jumps on China nod for recruitment for kidney disease drug study
Brief: Dimerix Says Investigational New Drug Application For DMX-200 Approved
Brief: Dimerix Ltd Entered Into Exclusive License Agreement
Australia's Dimerix jumps most in 10 years on drug commercialisation license
Brief: Dimerix Ltd Seeks Trading Halt Pending Announcement On Licensing Agreement
Dimerix gains as FDA approves commercial brand name for kidney disease
Brief: Dimerix Ltd Says FDA Approves Commercial Brand Name For Drug Candidate
Brief: Dimerix Ltd Receives Regulatory Approval To Expand Action3 Phase 3 Fsgs Kidney Trial Into Malaysia
Brief: Dimerix Ltd Says Loss For Year Attributable A$13.8 Mln
Australia's Dimerix rises on nod for development plan of potential paediatric drug
Brief: Dimerix Says EMA Accepted Paediatric Investigation Plan For Development Of DMX-200
Brief: Dimerix Says Entitlement Offer And Convertible Note To Raise A$12 Million
Brief: Dimerix Ltd Seeks Trading Halt
Brief: Dimerix Posts Total Comprehensive Loss For HY Attributable A$9.6 Million
Brief: Dimerix Says FDA Confirms Inclusion Of Paediatric Patients In Action3 Study Of DMX-200 For FSGS